Inflammaging in Neurodegeneration

Introduction

Inflammaging is a chronic, low-grade, sterile inflammation that develops with aging, representing one of the most significant biological hallmarks of organismal aging. This page provides detailed information about its molecular mechanisms, relationship to neurodegenerative diseases, and therapeutic implications. The term, coined by Dr. Claudio Franceschi in 2000, combines “inflammation” with “aging” to describe the persistent, subclinical inflammatory state that characterizes the aging process across species^{1'Inflammaging: an evolutionary perspective on immunosenescence (Nature Reviews Immunology, 2000)'2000 · DOI 10.1038/35013022Open reference}.

Inflammaging differs fundamentally from acute inflammation in several key aspects: it is chronic (lasting years to decades), sterile (occurring in the absence of pathogens), low-grade (involving modest elevations in inflammatory mediators), and systemic (affecting multiple organ systems simultaneously). This persistent inflammatory state is now recognized as a major driver of age-related diseases, including neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis^{2Inflammaging and brain aging (Nature Reviews Neuroscience, 2020)2020 · DOI 10.1038/s41583-020-00337-4Open reference}.

Overview

Inflammaging is characterized by elevated pro-inflammatory cytokines, chemokines, and acute-phase proteins in the absence of acute infection. The inflammatory milieu of aging includes consistently elevated levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β), among other mediators. These elevated inflammatory markers correlate strongly with mortality risk, cognitive decline, and functional impairment in elderly populations^{3Inflammaging and successful aging (Geroscience, 2022)2022 · DOI 10.1007/s11357-022-00586-4Open reference}.

The sources of inflammaging are multifactorial and include: (1) accumulated cellular senescence and the senescence-associated secretory phenotype (SASP); (2) chronic viral infections (particularly Epstein-Barr virus and cytomegalovirus); (3) gut microbiota dysbiosis and increased intestinal permeability (“leaky gut”); (4) mitochondrial dysfunction and cell-free mitochondrial DNA release; (5) accumulated nuclear and mitochondrial DNA damage; (6) decreased autophagy and impaired protein homeostasis; and (7) adipose tissue inflammation and visceral adiposity^{4Cellular Senescence in Age-Related Disorders (Nature Reviews Disease Primers, 2020)2020 · DOI 10.1038/s41586-020-03054-3Open reference}.

In the brain, inflammaging contributes to cognitive decline, synaptic dysfunction, and neuronal death through multiple interconnected pathways. The blood-brain barrier (BBB) becomes more permeable with age, allowing peripheral inflammatory signals to enter the central nervous system.同时, brain resident immune cells—particularly microglia—undergo phenotypic changes that amplify inflammatory responses^{5Microglial priming in aging and disease (Glia, 2019)2019 · DOI 10.1002/glia.23720Open reference}.

Molecular Mechanisms

Senescence-Associated Secretory Phenotype (SASP)

Cellular senescence is a state of irreversible cell cycle arrest that occurs in response to various stresses including telomere erosion, DNA damage, oncogenic stress, and mitochondrial dysfunction. Senescent cells accumulate in tissues with age, and their persistence is thought to contribute significantly to organismal aging through the SASP—a complex secretome that includes pro-inflammatory factors^{6The Senescence-Associated Secretory Phenotype (Cell, 2018)2018 · DOI 10.1016/j.cell.2018.05.012Open reference}.

The SASP comprises hundreds of proteins and bioactive molecules:

Pro-inflammatory cytokines:

• IL-6 (Interleukin-6): A key pleiotropic cytokine that promotes systemic inflammation, alters cellular metabolism, and affects neuroplasticity

• IL-8 (Interleukin-8/CXCL8): A chemokine that attracts neutrophils and promotes angiogenesis

• IL-1β (Interleukin-1 beta): A potent pro-inflammatory cytokine that amplifies NF-κB signaling

• TNF-α (Tumor necrosis factor alpha): A master regulator of inflammation that induces apoptosis and promotes tissue damage

Chemokines:

• CXCL1, CXCL8: Promote neutrophil recruitment

• CCL2 (MCP-1): Recruits monocytes and macrophages

• CXCL10 (IP-10): Promotes T-cell recruitment

Growth factors and remodeling factors:

• MMPs (Matrix metalloproteinases): Degrade extracellular matrix and disrupt tissue architecture

• PAI-1 (Plasminogen activator inhibitor-1): Promotes fibrosis and thrombosis

• VEGF (Vascular endothelial growth factor): Drives angiogenesis

The SASP creates a pro-inflammatory microenvironment that propagates inflammation to neighboring cells through paracrine signaling, a process termed “paracrine senescence.” Additionally, senescent cells escape immune surveillance through upregulation of anti-apoptotic pathways, allowing them to persist and secrete their inflammatory cargo indefinitely^{7Senescence and the SASP (Cell Cycle, 2010)2010 · DOI 10.4161/cc.9.17.12986Open reference}.

NLRP3 Inflammasome Activation

The NLRP3 (NLR family pyrin domain containing 3) inflammasome is a key driver of inflammaging and has been implicated in numerous neurodegenerative diseases. This cytosolic protein complex senses danger signals including:

• Mitochondrial dysfunction: Mitochondrial ROS, mitochondrial DNA (mtDNA), and cardiolipin release

• Oxative stress: Reactive oxygen species and nitrogen species

• Protein aggregates: Amyloid-beta (Aβ), α-synuclein, and hyperphosphorylated tau

• Cellular debris: Nucleotides, uric acid crystals, and ATP release from damaged cells

• Pathogen-associated molecular patterns: Bacterial and viral components

Upon activation, NLRP3 recruits the adaptor protein ASC and pro-caspase-1, forming the inflammasome complex. This leads to caspase-1 activation, which then cleaves pro-IL-1β and pro-IL-18 to their mature, secreted forms. The resulting inflammatory cascade propagates throughout the tissue microenvironment^{8NLRP3 inflammasome in neurodegeneration (Trends in Neurosciences, 2021)2021 · DOI 10.1016/j.tins.2021.02.005Open reference}.

In the brain, NLRP3 inflammasome activation in microglia drives chronic IL-1β release, which impairs amyloid clearance while promoting tau pathology spread. The inflammasome also contributes to neuroinflammation in Parkinson’s disease through activation by α-synuclein oligomers^{9NLRP3 and Alzheimer's disease (Acta Neuropathologica, 2020)2020 · DOI 10.1007/s00401-020-02139-5Open reference}.

Microglial Priming

Brain microglia become primed (sensitized) with aging, lowering their activation threshold and fundamentally altering their response to challenges. This age-related microglial transformation represents a critical nexus between systemic inflammaging and brain inflammation^{10Microglial aging in the CNS (Journal of Neuroinflammation, 2023)2023 · DOI 10.1186/s12974-023-01839-1Open reference}.

Microglial priming is characterized by:

• Altered morphology: Aged microglia show increased complexity and process motility

• Elevated baseline activation: Increased expression of MHC-II and pattern recognition receptors

• Dysregulated signaling: Enhanced NF-κB and MAPK signaling in response to stimuli

• Impaired surveillance: Reduced homeostatic monitoring of the microenvironment

• Accumulated DNA damage: Microglial aging involves cellular senescence

Primed microglia exhibit enhanced pro-inflammatory responses to secondary stimuli, a phenomenon called “microglial priming.” This creates a feedforward loop where age-related challenges trigger exaggerated neuroinflammation. The concept of “priming” explains why peripheral infections (like pneumonia or urinary tract infections) can trigger acute cognitive decline in older adults—a phenomenon termed delirium^{2Inflammaging and brain aging (Nature Reviews Neuroscience, 2020)2020 · DOI 10.1038/s41583-020-00337-4Open reference}0.

NF-κB Signaling Pathway

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway serves as the master transcriptional regulator of inflammaging. This transcription factor controls the expression of hundreds of inflammatory genes, including cytokines, chemokines, adhesion molecules, and enzymes involved in oxidative stress^{2Inflammaging and brain aging (Nature Reviews Neuroscience, 2020)2020 · DOI 10.1038/s41583-020-00337-4Open reference}1.

NF-κB is activated by:

• Pro-inflammatory cytokines (IL-1β, TNF-α)

• Pattern recognition receptors (TLRs, NLRs)

• Oxidative stress

• DNA damage

• Mitochondrial dysfunction

The canonical NF-κB pathway involves IκB kinase (IKK) phosphorylation of IκBα, releasing p50/p65 dimers to translocate to the nucleus. Chronic NF-κB activation in aging tissues creates a self-perpetuating inflammatory loop that drives tissue dysfunction and contributes to neurodegeneration.

Telomere Attrition and DNA Damage Response

Telomere shortening with age triggers the DNA damage response (DDR), which activates NF-κB and promotes inflammation. Critically short telomeres become recognized as DNA damage, triggering p53 and NF-κB pathways that drive SASP expression. Leukocyte telomere length correlates with inflammatory marker levels and cognitive decline in elderly populations^{2Inflammaging and brain aging (Nature Reviews Neuroscience, 2020)2020 · DOI 10.1038/s41583-020-00337-4Open reference}2.

Inflammaging in Alzheimer’s Disease

In Alzheimer’s disease (AD), the most common neurodegenerative disorder, inflammaging interacts with the two hallmark pathologies—amyloid-beta (Aβ) plaques and neurofibrillary tau tangles—in a complex bidirectional relationship^{2Inflammaging and brain aging (Nature Reviews Neuroscience, 2020)2020 · DOI 10.1038/s41583-020-00337-4Open reference}3.

Amyloid-Beta and Inflammation

Aβ oligomers activate the NLRP3 inflammasome in microglia through multiple mechanisms:

• Direct recognition by TLRs and CD36

• Internalization and lysosomal destabilization

• Mitochondrial dysfunction and ROS generation

This activation drives chronic IL-1β release that impairs amyloid clearance while promoting tau pathology spread. The inflammatory response to Aβ also includes TNF-α, IL-6, and chemokine production, creating a neurotoxic microenvironment that contributes to synaptic dysfunction and neuronal loss^{2Inflammaging and brain aging (Nature Reviews Neuroscience, 2020)2020 · DOI 10.1038/s41583-020-00337-4Open reference}4.

Tau and Inflammation

Pathological tau species (hyperphosphorylated tau, oligomers, tangles) activate microglia through multiple receptors:

• TLR2 and TLR4: Pattern recognition receptors that recognize misfolded proteins

• CD36: Scavenger receptor involved in Aβ and tau clearance

• RAGE (Receptor for advanced glycation end-products): Binds Aβ and mediates neurotoxicity

The resulting neuroinflammation creates a self-perpetuating cycle where inflammatory kinases (CDK5, GSK-3β) promote tau phosphorylation, while tau pathology further activates microglia. This bidirectional relationship between tau and inflammation accelerates disease progression^{2Inflammaging and brain aging (Nature Reviews Neuroscience, 2020)2020 · DOI 10.1038/s41583-020-00337-4Open reference}5.

Inflammatory Biomarkers in AD

Key inflammatory markers elevated in AD include:

• IL-6: Elevated in both cerebrospinal fluid (CSF) and plasma; correlates with cognitive decline

• IL-1β: Increased in brain tissue and CSF; drives tau pathology

• TNF-α: Elevated in serum and CSF; associated with disease severity

• C-reactive protein (CRP): Systemic inflammation predicts AD risk

• TGF-β: Paradoxically elevated but functionally impaired

• YKL-40 (chitinase-3-like protein 1): Microglial marker elevated in CSF

The APOE ε4 allele, the strongest genetic risk factor for sporadic AD, modulates microglial responses to Aβ and influences inflammatory pathways^{2Inflammaging and brain aging (Nature Reviews Neuroscience, 2020)2020 · DOI 10.1038/s41583-020-00337-4Open reference}6.

Inflammaging in Parkinson’s Disease

Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Inflammaging contributes to PD pathogenesis through multiple interconnected mechanisms^{2Inflammaging and brain aging (Nature Reviews Neuroscience, 2020)2020 · DOI 10.1038/s41583-020-00337-4Open reference}7.

Microglial Activation in Substantia Nigra

The substantia nigra is particularly vulnerable to inflammatory damage due to several factors:

• High baseline metabolic activity and ROS production

• Neuromelanin accumulation, which can activate microglia

• Rich dopaminergic innervation that undergoes autooxidation

• High iron content promoting oxidative stress

Chronic activation of substantia nigra microglia leads to progressive dopaminergic neuron loss. Postmortem studies show increased HLA-DR positive microglia in the substantia nigra of PD patients, and PET imaging using TSPO ligands confirms microglial activation in living PD patients^{2Inflammaging and brain aging (Nature Reviews Neuroscience, 2020)2020 · DOI 10.1038/s41583-020-00337-4Open reference}8.

Alpha-Synuclein and Inflammation

α-Synuclein, the protein that forms Lewy bodies in PD, activates microglia through:

• Externalization of oligomeric and fibrillar species

• Activation of TLR2, TLR4, and CD36

• NLRP3 inflammasome activation

• Propagation of inflammation between brain regions

The prion-like spreading of α-synuclein pathology may be facilitated by inflammatory-mediated changes in cellular transport and degradation pathways^{2Inflammaging and brain aging (Nature Reviews Neuroscience, 2020)2020 · DOI 10.1038/s41583-020-00337-4Open reference}9.

Peripheral Inflammation and BBB

Systemic inflammaging increases blood-brain barrier (BBB) permeability, allowing peripheral immune cells and inflammatory mediators to enter the brain. This “inflammaging-gut-brain axis” connects peripheral inflammation to central nervous system pathology:

• Elevated peripheral cytokines (IL-6, TNF-α, IL-1β) reach the brain through circumventricular organs

• Monocytes migrate into the brain parenchyma

• Peripheral T cells enter through damaged BBB regions

• Circulating pro-inflammatory factors alter brain endothelial cell function

Gut-Brain Axis

Age-related gut dysbiosis and intestinal inflammation may initiate or accelerate PD pathology through vagal nerve signaling. The gut microbiome in PD patients shows altered composition, and germ-free animals are protected from α-synuclein pathology. This connection provides a mechanistic basis for the Braak hypothesis, which proposes that PD pathology initiates in the enteric nervous system and propagates retrogradely through the vagus nerve to the brain^{3Inflammaging and successful aging (Geroscience, 2022)2022 · DOI 10.1007/s11357-022-00586-4Open reference}0.

Inflammaging in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) shows particularly robust inflammatory components, with neuroinflammation present at all disease stages and across multiple brain regions^{3Inflammaging and successful aging (Geroscience, 2022)2022 · DOI 10.1007/s11357-022-00586-4Open reference}1.

Cellular Players in ALS Inflammation

• Activated microglia and astrocytes: Prominent in motor cortex and spinal cord

• Oligodendrocyte dysfunction: Contributes to axonal energy failure

• Monocyte/macrophage infiltration: From peripheral circulation

• T cell infiltration: Particularly CD4+ and CD8+ T cells

Inflammatory Mediators in ALS

Elevated pro-inflammatory cytokines in cerebrospinal fluid include:

• IL-6

• TNF-α

• IL-1β

• MCP-1 (CCL2)

These mediators create a hostile microenvironment that accelerates motor neuron degeneration. The interplay between motor neuron vulnerability and inflammatory cascades represents a therapeutic target being actively investigated^{3Inflammaging and successful aging (Geroscience, 2022)2022 · DOI 10.1007/s11357-022-00586-4Open reference}2.

Genetic Insights

ALS genes influence inflammatory pathways:

• C9orf72: Regulates lysosomal trafficking and immune function; loss-of-function causes immune dysregulation

• SOD1: Mutant SOD1 activates microglia and astrocytes

• TDP-43: Regulates inflammatory gene expression

• FUS: Affects RNA splicing in immune cells

Inflammaging in Other Neurodegenerative Diseases

Frontotemporal Dementia

Frontotemporal dementia (FTD) shows significant neuroinflammation, particularly in the frontal and temporal cortices. Microglial activation correlates with disease severity and progression, and inflammatory biomarkers (IL-6, TNF-α) are elevated in FTD patient CSF^{3Inflammaging and successful aging (Geroscience, 2022)2022 · DOI 10.1007/s11357-022-00586-4Open reference}3.

Huntington’s Disease

Huntington’s disease (HD) features prominent neuroinflammation starting early in disease course. Mutant huntingtin protein activates microglia and astrocytes, and peripheral inflammatory markers predict disease progression. The inflammatory response contributes to striatal neuron loss and cognitive decline^{3Inflammaging and successful aging (Geroscience, 2022)2022 · DOI 10.1007/s11357-022-00586-4Open reference}4.

Multiple Sclerosis

While primarily an autoimmune demyelinating disease, multiple sclerosis (MS) shows features of inflammaging, with chronic inflammation continuing despite immunosuppressive therapies. Age-related changes in immune function affect disease progression and treatment response^{3Inflammaging and successful aging (Geroscience, 2022)2022 · DOI 10.1007/s11357-022-00586-4Open reference}5.

Therapeutic Strategies

Senolytics

Drugs that selectively eliminate senescent cells have shown promise in preclinical models of neurodegeneration:

The Dasatinib + Quercetin (D+Q) combination has shown cognitive benefits in animal models and is being evaluated in clinical trials for Alzheimer’s disease^{3Inflammaging and successful aging (Geroscience, 2022)2022 · DOI 10.1007/s11357-022-00586-4Open reference}6.

Anti-inflammatory Therapies

Immunomodulatory Approaches

• Microglial modulation: Targeting TREM2, which regulates microglial phagocytosis

• CSF1R inhibitors: Deplete or modulate microglia

• NAD+ boosting: SIRT1 activation reduces inflammation

• Autophagy enhancement: Reduces protein aggregate burden

Lifestyle Interventions

Exercise: Regular physical activity reduces systemic inflammation through multiple mechanisms, including decreased visceral fat, improved gut microbiome, reduced SASP, and increased anti-inflammatory cytokines (IL-10, TGF-β)^{3Inflammaging and successful aging (Geroscience, 2022)2022 · DOI 10.1007/s11357-022-00586-4Open reference}7.

Caloric restriction: Reduces inflammatory markers and extends healthspan through metabolic remodeling, including increased autophagy and reduced mTOR signaling.

Diet: Mediterranean diet and omega-3 fatty acids demonstrate anti-inflammatory effects through:

• Reduced prostaglandin synthesis

• Increased resolvins and protectins

• Improved gut microbiome composition

Sleep: Adequate sleep (7-8 hours) reduces inflammatory markers, while sleep disruption increases IL-6 and CRP levels.

Stress management: Chronic stress increases inflammation; mindfulness and stress reduction reduce inflammatory biomarkers.

Biomarkers of Inflammaging

Clinical and research use of inflammaging biomarkers includes:

Systemic inflammatory markers:

• High-sensitivity C-reactive protein (hs-CRP)

• IL-6 (gold standard)

• TNF-α

• IL-1β

• Soluble IL-6 receptor

Cellular senescence markers:

• p16INK4a expression

• Senescence-associated β-galactosidase

• SASP factors in plasma

Brain-specific markers:

• YKL-40 (microglial activation)

• Neurofilament light chain (neurodegeneration)

• Total tau and phosphorylated tau

Cross-Linking

• Microglia Neuroinflammation

• NLRP3 Inflammasome

• Cellular Senescence

• Metaflammation

• Alzheimer’s Pathogenesis

• Parkinson’s Pathogenesis

• Microglial Activation

• Amyloid-Beta

• Alpha-Synuclein

• Tau Protein

• Blood-Brain Barrier

• Gut-Brain Axis

See Also

• Microglia Neuroinflammation

• NLRP3 Inflammasome

• Cellular Senescence

• Metaflammation

• Alzheimer’s Pathogenesis

• Parkinson’s Pathogenesis

External Links

• PubMed

• KEGG Pathways

flowchart TD
    A["Chronic Low-Grade Inflammation"]  -->  B["Increased Pro-inflammatory Cytokines"]
    B  -->  C["IL-6, TNF-alpha, IL-1beta"]
    C  -->  D["Cellular Senescence"]
    D  -->  E["SASP Secretion"]
    E  -->  F["Paracrine Senescence"]
    F  -->  B

    C  -->  G["NF-kappaB Activation"]
    G  -->  H["Inflammasome Activation"]
    H  -->  I["Microglial Priming"]
    I  -->  J["Enhanced Neuroinflammatory Response"]

    B  -->  K["Impaired Autophagy"]
    K  -->  L["Protein Aggregate Accumulation"]
    L  -->  M["Neurodegeneration"]

    N["Aging"]  -->  A
    N  -->  D
    O["DNA Damage"]  -->  G
    P["Mitochondrial Dysfunction"]  -->  A
    P  -->  G

    style A fill:#2d0f0f
    style M fill:#1a0a1f

Future Research Directions

The field of inflammaging in neurodegeneration continues to evolve, with several key research directions emerging:

Single-Cell Approaches

Single-cell RNA sequencing and spatial transcriptomics are revolutionizing our understanding of inflammaging by:

• Identifying rare cell populations driving inflammation

• Characterizing microglial states across disease stages

• Mapping inflammatory trajectories in the aging brain

• Understanding cell-type specific responses to therapy

Causal Mechanisms

Establishing causality between inflammaging and neurodegeneration remains challenging. Key approaches include:

• Genetic Mendelian randomization studies

• Longitudinal biomarker studies

• Intervention trials targeting inflammation

• Systems biology integration

Therapeutic Translation

Translating basic science insights into clinical benefits requires:

• Validated biomarkers for patient selection

• Brain-penetrant anti-inflammatory agents

• Precision medicine approaches based on inflammatory endotypes

• Combination therapies targeting multiple pathways

Multi-Omics Integration

Integrating genomics, transcriptomics, proteomics, and metabolomics data will help identify:

• Molecular signatures of successful brain aging

• Predictive biomarkers for disease progression

• Novel therapeutic targets

• Individual variation in inflammatory responses